Literature DB >> 25846476

Should patients prescribed long-term low-dose aspirin receive proton pump inhibitors? A systematic review and meta-analysis.

A Tran-Duy1,2, F H Vanmolkot3, M A Joore1, A W Hoes2, C D A Stehouwer3,4.   

Abstract

BACKGROUND: Several clinical guidelines recommend the use of proton pump inhibitors (PPIs) in patients taking low-dose aspirin but report no or limited supporting data. We conducted a systematic review and meta-analysis to examine the effects of co-administration of PPIs in patients taking low-dose aspirin on the risks of adverse gastrointestinal (GI) and cardiovascular (CV) events, and on patient adherence to aspirin.
METHODS: We searched PUBMED, EMBASE and Cochrane Central Register of Controlled Trials databases for relevant articles published through November 2013. We included randomised controlled trials (RCTs) and observational studies in patients taking low-dose aspirin with and without PPIs. Risk of bias was assessed using the Cochrane Collaboration's tool (for RCTs) and the Newcastle-Ottawa Scale (for observational studies). Pooled risk ratios (RRs) were computed using a random-effects model.
RESULTS: We included 13 studies, of which 12 (2 RCTs and 10 observational studies) reported on GI events, and one (cohort study) on both GI bleeding and CV events. No study reported on adherence to aspirin. Co-administration of PPIs in patients receiving low-dose aspirin was associated with risk reductions of 73% (RR 0.27, 95% CI 0.17-0.42) and 50% (RR 0.50, 95% CI 0.32-0.80) in the occurrence of peptic ulcer and GI bleeding respectively. There was evidence of bias in publications reporting on the GI events.
CONCLUSIONS: The practice of co-prescribing PPIs in patients taking low-dose aspirin is supported by some data, but the evidence is rather weak. It currently remains unclear whether the benefits of co-administration of PPIs in users of low-dose aspirin outweigh their potential harms.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25846476     DOI: 10.1111/ijcp.12634

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  5 in total

Review 1.  Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach.

Authors:  Sagar Dugani; Jeffrey M Ames; JoAnn E Manson; Samia Mora
Journal:  Curr Atheroscler Rep       Date:  2018-02-21       Impact factor: 5.113

Review 2.  Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents.

Authors:  Parth J Parekh; Edward C Oldfield; David A Johnson
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

3.  Quantifying Candidacy for Deprescribing of Proton Pump Inhibitors among Long-Term Care Residents.

Authors:  Alanna Doell; Ashley Walus; Jaclyn To; Allison Bell
Journal:  Can J Hosp Pharm       Date:  2018-10-31

4.  Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management.

Authors:  Preya Janubhai Patel; Kelly Lee Hayward; Rathiga Rudra; Leigh Ula Horsfall; Fabrina Hossain; Suzanne Williams; Tracey Johnson; Nigel Neil Brown; Nivene Saad; Andrew Donald Clouston; Katherine Anne Stuart; Patricia Casarolli Valery; Katharine Margaret Irvine; Anthony William Russell; Elizabeth Ellen Powell
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

5.  Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial.

Authors:  Suzanne E Mahady; Karen L Margolis; Andrew Chan; Galina Polekhina; Robyn L Woods; Rory Wolfe; Mark R Nelson; Jessica E Lockery; Erica M Wood; Christopher Reid; Michael E Ernst; Anne Murray; Ltp Thao; John J McNeil
Journal:  Gut       Date:  2020-08-03       Impact factor: 31.793

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.